Massive Bio publishes landmark prospective study demonstrating AI-driven clinical trial matching at scale in 3,804 cancer ...

Siemens Healthineers joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease ...

Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute ...

The last time I spoke about Tourmaline Bio (TRML) it was with respect to a Seeking Alpha article entitled "Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting." In this article, I ...

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population; Phase 1b data demonstrate ...

BOSTON--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today ...

The last time I spoke about Upstream Bio, Inc. (UPB) it was in a Seeking Alpha article entitled "Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation." With respect to this ...

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies ...

INmune Bio, Inc. announced positive results from a double-blinded, randomized clinical trial named "MissionEB" for its product CORDStrom, aimed at treating Recessive Dystrophic Epidermolysis Bullosa ...

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria ...

- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, ...